SUPN - Supernus Pharmaceuticals Inc Stock Price, Fair Value and News

30.30USD+0.90 (+3.06%)Delayed as of 22 Apr 2024, 02:06 pm ET

Market Summary

USD30.30+0.90

Delayedas of 22 Apr 2024, 02:06 pm

3.06%

SUPN Alerts

1 major insider sales recently.

SUPN Stock Price

View Fullscreen

SUPN RSI Chart

SUPN Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

62.69

Price/Sales (Trailing)

2.63

EV/EBITDA

12.55

Price/Free Cashflow

17.28

SUPN Price/Sales (Trailing)

SUPN Profitability

EBT Margin

6.05%

Return on Equity

2.81%

Return on Assets

1.99%

Free Cashflow Yield

5.79%

SUPN Fundamentals

SUPN Revenue

Revenue (TTM)

610.5M

Rev. Growth (Yr)

-13.24%

Rev. Growth (Qtr)

13.51%

SUPN Earnings

Earnings (TTM)

25.6M

Earnings Growth (Yr)

-1.0K%

Earnings Growth (Qtr)

-1.8K%

Breaking Down SUPN Revenue

52 Week Range

26.8438.61

(Low)(High)

Last 7 days

-2.8%

Last 30 days

-15.7%

Last 90 days

6.3%

Trailing 12 Months

-21.5%

How does SUPN drawdown profile look like?

SUPN Financial Health

Current Ratio

1.56

SUPN Investor Care

Shares Dilution (1Y)

1.06%

Diluted EPS (TTM)

0.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	668.5M	634.0M	610.5M	0
2022	601.3M	630.1M	659.0M	667.2M
2021	556.4M	571.0M	564.3M	579.8M
2020	402.3M	424.3M	477.3M	520.4M
2019	403.9M	409.1M	408.2M	392.8M
2018	335.1M	358.8M	381.4M	408.9M
2017	228.4M	252.6M	276.2M	302.2M
2016	162.9M	178.9M	196.3M	215.0M
2015	112.3M	118.3M	135.0M	147.5M
2014	21.0M	50.3M	71.8M	92.7M
2013	1.4M	1.6M	2.8M	12.0M
2012	679.3K	555.7K	432.0K	1.5M
2011	0	25.6M	13.2M	803.0K
2009	0	0	0	37.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Supernus Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 21, 2024	bhatt padmanabh p.	acquired	366,622	25.3	14,491	sr. vp of ip, cso
Mar 21, 2024	bhatt padmanabh p.	sold	-511,677	35.31	-14,491	sr. vp of ip, cso
Mar 20, 2024	bhatt padmanabh p.	sold	-14,124	35.31	-400	sr. vp of ip, cso
Mar 20, 2024	bhatt padmanabh p.	acquired	10,120	25.3	400	sr. vp of ip, cso
Mar 19, 2024	bhatt padmanabh p.	acquired	312,809	25.3	12,364	sr. vp of ip, cso
Mar 19, 2024	bhatt padmanabh p.	sold	-436,573	35.31	-12,364	sr. vp of ip, cso
Mar 13, 2024	bhatt padmanabh p.	acquired	1,098,520	17.6141	62,366	sr. vp of ip, cso
Mar 13, 2024	bhatt padmanabh p.	sold	-2,104,290	33.741	-62,366	sr. vp of ip, cso
Mar 12, 2024	bhatt padmanabh p.	acquired	50,414	12.98	3,884	sr. vp of ip, cso
Mar 12, 2024	bhatt padmanabh p.	sold	-128,133	32.99	-3,884	sr. vp of ip, cso

Which funds bought or sold SUPN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	SJS Investment Consulting Inc.	reduced	-20.00	-8.00	137	-%
Apr 18, 2024	Phocas Financial Corp.	unchanged	-	-3,514,480	3,518	0.01%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-0.83	179,094	1,239,460	-%
Apr 18, 2024	Tributary Capital Management, LLC	reduced	-0.41	1,741,630	11,762,400	0.96%
Apr 18, 2024	Park Place Capital Corp	unchanged	-	1,024	6,754	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	-	-%
Apr 18, 2024	Congress Wealth Management LLC / DE /	added	37.78	2,330,060	6,064,790	0.10%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	206	1,364	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	71.45	686,542	1,359,080	0.07%
Apr 16, 2024	CAMPBELL NEWMAN ASSET MANAGEMENT INC	added	2.72	258,473	1,484,980	0.12%

Are Funds Buying or Selling SUPN?

Are funds buying SUPN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SUPN

No. of Funds

SUPN Alerts

1 major insider sales recently.

Unveiling Supernus Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	8.51%	4,650,000	SC 13G/A
Feb 14, 2024	macquarie group ltd	5.01%	2,737,721	SC 13G
Feb 13, 2024	vanguard group inc	11.38%	6,214,731	SC 13G/A
Jan 19, 2024	blackrock inc.	19.0%	10,381,318	SC 13G/A
Feb 14, 2023	armistice capital, llc	8.06%	4,356,000	SC 13G/A
Feb 09, 2023	vanguard group inc	10.71%	5,789,960	SC 13G/A
Jan 23, 2023	blackrock inc.	17.8%	9,604,073	SC 13G/A
Feb 15, 2022	armistice capital, llc	7.8%	4,136,000	SC 13G/A
Jan 27, 2022	blackrock inc.	15.9%	8,451,022	SC 13G/A
Jan 26, 2022	blackrock inc.	15.9%	8,451,022	SC 13G/A

Recent SEC filings of Supernus Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 08, 2024	8-K	Current Report
Mar 25, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 21, 2024	4	Insider Trading
Mar 19, 2024	144	Notice of Insider Sale Intent
Mar 15, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 13, 2024	144	Notice of Insider Sale Intent
Mar 12, 2024	144	Notice of Insider Sale Intent
Feb 29, 2024	4	Insider Trading

Peers (Alternatives to Supernus Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	356.3B	85.2B	-5.03%	-9.57%	10.14	4.18	6.46%	95.94%
MRK	318.7B	60.1B	1.61%	10.23%	873.24	5.3	1.40%	-97.49%
PFE	146.8B	46.5B	-6.17%	-34.78%	-105.7	3.15	42.59%	-114.62%
AMGN	144.1B	28.2B	-1.51%	10.46%	21.46	5.11	7.09%	2.52%
GILD	83.2B	27.1B	-9.77%	-21.18%	14.68	3.07	-0.60%	23.36%
TEVA	14.4B	15.8B	-4.60%	54.01%	-25	0.91	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	-1.63%	-14.16%	-328.65	0.9	4.58%	90.97%
ALKS	4.0B	1.7B	-13.93%	-17.76%	11.2	2.4	49.61%	324.78%
BHC	3.2B	8.8B	-9.38%	13.00%	-5.36	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-9.13%	-7.04%	13.99	2.99	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-12.63%	-26.38%	-3.8	1.8	24.65%	80.36%
TXMD	21.6M	1.3M	-20.43%	-49.32%	-2.1	16.56	-98.14%	-109.18%
ACRX	16.6M	-	-10.09%	36.11%	-0.9	0.22	2882.68%	-138.52%
AGRX	2.6M	19.6M	-34.48%	-94.22%	-0.18	0.13	80.00%	43.08%
ACOR	546.5K	117.6M	-96.48%	-95.45%	0	0	-0.79%	-283.60%

Supernus Pharmaceuticals Inc News

Latest updates

Supernus Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	13.5%	154	136	154	167	177	170	153	159	148	141	131	144	155	127	95.00	100	102	105	85.00	116	103
Costs and Expenses	-4.8%	146	153	149	133	179	159	151	153	116	107	118	101	99.00	81.00	66.00	60.00	62.00	62.00	60.00	76.00	66.00
S&GA Expenses	-4.7%	83.00	87.00	86.00	74.00	112	100	90.00	102	72.00	70.00	61.00	57.00	54.00	48.00	42.00	34.00	39.00	40.00	41.00	37.00	41.00
R&D Expenses	-7.1%	23.00	24.00	21.00	18.00	20.00	16.00	21.00	31.00	20.00	15.00	15.00	18.00	17.00	22.00	19.00	20.00	17.00	17.00	15.00	30.00	20.00
EBITDA Margin	11.9%	0.20*	0.18*	0.21*	0.22*	0.15*	0.18*	0.20*	0.19*	0.25*	0.29*	0.32*	0.36*	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	1.00	2.00	-2.96	2.00	2.00	2.00	-14.97	6.00	5.00	6.00	-15.14	6.00	6.00	6.00	-12.10	6.00	5.00	1.00	-3.37	4.00
Income Taxes	258.7%	26.00	-16.30	-7.93	10.00	-2.19	3.00	-10.89	-0.39	7.00	8.00	5.00	9.00	13.00	13.00	8.00	8.00	11.00	10.00	6.00	13.00	8.00
Earnings Before Taxes	157.7%	10.00	-17.13	9.00	35.00	-0.44	11.00	15.00	2.00	29.00	31.00	11.00	40.00	53.00	47.00	29.00	41.00	40.00	43.00	24.00	39.00	36.00
EBT Margin	44.2%	0.06*	0.04*	0.08*	0.09*	0.04*	0.09*	0.13*	0.13*	0.20*	0.24*	0.27*	0.32*	-	-	-	-	-	-	-	-	-
Net Income	-1822.5%	-15.98	-0.83	17.00	25.00	2.00	8.00	26.00	2.00	22.00	24.00	6.00	31.00	40.00	35.00	22.00	33.00	29.00	33.00	18.00	26.00	28.00
Net Income Margin	-38.6%	0.04*	0.07*	0.08*	0.09*	0.06*	0.09*	0.12*	0.09*	0.14*	0.18*	0.20*	0.24*	-	-	-	-	-	-	-	-	-
Free Cashflow	287.7%	36.00	-19.03	49.00	27.00	14.00	72.00	3.00	49.00	-4.11	46.00	35.00	32.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-0.6%	1,285	1,293	1,792	1,703	1,693	1,695	1,640	1,689	1,555	1,573	1,507	1,504	1,510	1,491	1,190	1,160	1,107	1,064	1,025	978	923
Current Assets	6.1%	449	424	883	734	664	625	569	602	668	639	586	630	552	557	557	473	427	391	420	493	391
Cash Equivalents	284.5%	95.00	25.00	58.00	93.00	111	173	116	203	215	224	256	289	204	211	226	181	117	87.00	123	192	124
Inventory	-7.8%	83.00	91.00	91.00	92.00	83.00	85.00	89.00	86.00	60.00	58.00	50.00	48.00	42.00	35.00	24.00	27.00	26.00	26.00	27.00	26.00	23.00
Net PPE	-3.5%	14.00	14.00	15.00	15.00	-	-	17.00	17.00	-	-	38.00	38.00	17.00	18.00	18.00	17.00	10.00	4.00	4.00	4.00	7.00
Goodwill	0%	117	117	117	117	117	115	115	118	40.00	78.00	78.00	78.00	89.00	88.00	-	-	-	-	-	-	-
Liabilities	-0.1%	373	373	880	816	840	854	811	873	745	787	753	759	801	825	576	565	550	541	545	525	501
Current Liabilities	13.8%	288	253	732	688	726	736	285	315	235	283	241	245	300	269	168	161	150	144	152	161	138
LT Debt, Current	-	-	-	-	-	401	401	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	379	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-0.8%	912	920	912	886	853	841	828	816	810	786	754	745	709	666	613	595	557	523	480	453	422
Retained Earnings	-3.2%	481	497	498	481	456	454	446	380	377	356	332	326	296	256	221	200	166	138	105	86.00	61.00
Additional Paid-In Capital	1.8%	432	424	416	408	401	390	383	434	429	424	416	409	403	399	392	388	384	379	374	370	365
Shares Outstanding	0%	54.00	54.00	54.00	54.00	54.00	53.00	53.00	53.00	53.00	53.00	53.00	53.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	1,546	-	-	-	1,635	-	-	-	1,205	-	-	-	1,678	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	290.1%	35,875	-18,874	49,126	27,564	13,841	71,119	4,302	48,763	-4,110	46,274	36,200	31,933	5,599	91,951	8,916	43,791	37,658	28,687	32,993	32,849	62,448
Share Based Compensation	30.1%	7,920	6,088	6,306	4,261	4,985	4,297	4,025	4,036	4,027	5,476	4,371	3,121	4,490	4,962	3,988	3,623	3,914	4,022	3,287	2,991	2,597
Cashflow From Investing	-42.6%	34,634	60,296	239,780	-48,765	-82,232	-15,679	-69,987	76,130	-5,704	-80,894	-71,445	49,345	-11,302	-108,180	35,438	19,438	-8,355	-65,761	-103,246	34,330	25,337
Cashflow From Financing	100.0%	-230	-478,916	80,174	2,829	6,455	2,273	-22,034	-136,740	1,324	2,749	2,247	3,069	-979	1,437	32.00	1,263	242	1,640	783	1,251	828

SUPN Income Statement

2023-09-30

Condensed Consolidated Statements of Earnings (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues
Total revenues	$ 153,880	$ 177,353	$ 443,207	$ 499,910
Costs and expenses
Cost of goods sold	19,601	25,878	64,152	64,267
Research and development	22,655	19,554	68,246	56,778
Selling, general and administrative	82,700	112,314	255,079	303,249
Amortization of intangible assets	21,242	20,644	61,316	61,932
Contingent consideration expense (gain)	(456)	486	(1,313)	1,894
Total costs and expenses	145,742	178,876	447,480	488,120
Operating earnings (loss)	8,138	(1,523)	(4,273)	11,790
Other income (expense)
Interest expense	0	(1,724)	(2,415)	(5,476)
Interest and other income, net	1,751	2,803	8,467	19,289
Total other income (expense)	1,751	1,079	6,052	13,813
Earnings (loss) before income taxes	9,889	(444)	1,779	25,603
Income tax expense (benefit)	25,865	(2,193)	1,638	(9,627)
Net earnings (loss)	$ (15,976)	$ 1,749	$ 141	$ 35,230
Earnings (loss) per share
Basic (in dollars per share)	$ (0.29)	$ 0.03	$ 0.00	$ 0.66
Diluted (in dollars per share)	$ (0.29)	$ 0.03	$ 0.00	$ 0.62
Weighted average shares outstanding
Basic (in shares)	54,608,963	53,789,674	54,498,687	53,517,838
Diluted (in shares)	54,608,963	55,034,838	55,574,922	61,543,121
Net product sales
Revenues
Total revenues	$ 149,004	$ 172,724	$ 417,915	$ 485,647
Royalty revenues
Revenues
Total revenues	$ 4,876	$ 4,629	$ 25,292	$ 14,263

SUPN Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 94,985	$ 93,120
Marketable securities	105,204	368,214
Accounts receivable, net	141,764	165,497
Inventories, net	83,480	91,541
Prepaid expenses and other current assets	23,927	15,779
Total current assets	449,360	734,151
Long-term marketable securities	25,125	93,896
Property and equipment, net	13,688	15,173
Intangible assets, net	641,147	702,463
Goodwill	117,019	117,019
Other assets	38,821	39,806
Total assets	1,285,160	1,702,508
Current liabilities
Accounts payable and accrued liabilities	78,471	96,342
Accrued product returns and rebates	162,473	151,665
Convertible notes, net	0	401,968
Contingent consideration, current portion	45,880	21,120
Other current liabilities	710	16,863
Total current liabilities	287,534	687,958
Contingent consideration, long-term	7,774	33,847
Operating lease liabilities, long-term	33,841	35,998
Deferred income tax liabilities, net	35,224	49,809
Other liabilities	8,596	8,692
Total liabilities	372,969	816,304
Stockholders’ equity
Common stock, $0.001 par value; 130,000,000 shares authorized; 54,630,758 and 54,253,796 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	55	54
Additional paid-in capital	431,956	408,115
Accumulated other comprehensive loss, net of tax	(1,206)	(3,210)
Retained earnings	481,386	481,245
Total stockholders’ equity	912,191	886,204
Total liabilities and stockholders’ equity	$ 1,285,160	$ 1,702,508

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

CEO	Mr. Jack A. Khattar
WEBSITE	supernus.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	612

Supernus Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Supernus Pharmaceuticals Inc? What does SUPN stand for in stocks?

SUPN is the stock ticker symbol of Supernus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Supernus Pharmaceuticals Inc (SUPN)?

As of Fri Apr 19 2024, market cap of Supernus Pharmaceuticals Inc is 1.61 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SUPN stock?

You can check SUPN's fair value in chart for subscribers.

What is the fair value of SUPN stock?

You can check SUPN's fair value in chart for subscribers. The fair value of Supernus Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Supernus Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SUPN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Supernus Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SUPN is over valued or under valued. Whether Supernus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Supernus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SUPN.

What is Supernus Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, SUPN's PE ratio (Price to Earnings) is 62.69 and Price to Sales (PS) ratio is 2.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SUPN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Supernus Pharmaceuticals Inc's stock?

In the past 10 years, Supernus Pharmaceuticals Inc has provided 0.134 (multiply by 100 for percentage) rate of return.